Cipla Shares Surge 4% as Citi Eyes 90-Day Growth Catalysts
Pharmaceutical giant Cipla saw its stock rally by 4% to a high of Rs 1,409 on the BSE following a bullish update from international brokerage Citi. By placing the stock on a "90-day Positive Catalyst Watch," Citi has signaled that several imminent regulatory and product milestones could trigger a significant price re-rating.
US Market Triggers and Product Milestones
The primary driver behind Citi's optimism lies in a series of upcoming developments in the United States market. The brokerage has maintained a 'Buy' rating with a target price of Rs 1,700, representing a potential upside of 25.55%.
A major near-term catalyst is the expected approval of gFlovent from Cipla’s Goa facility, which is anticipated to bolster US revenue growth. Additionally, the anticipated launch of gVentolin is expected to provide further momentum. Citi also highlighted Cipla's strong competitive position in the US, noting that its Nintedanib product has already captured nearly 50% of the market share. Following a period of recent weakness, the US business is now positioned for a significant revenue rebound.
Domestic Resilience and Regulatory Outlook
On the domestic front, Cipla’s India business remains a powerhouse, contributing nearly two-thirds of the company's EBITDA. The brokerage noted a steady recovery in the company's respiratory portfolio, which continues to drive performance in the Indian market.
Further upside could stem from regulatory clearances. A re-inspection of the Indore plant is expected at any time; a favorable outcome and subsequent USFDA clearance would serve as a powerful additional catalyst. Moreover, easing geopolitical tensions are expected to alleviate previous concerns regarding raw material costs and margin volatility.
Valuation Advantage Over Domestic Peers
Despite a challenging recent financial period—where Q4 consolidated net profit fell 55% YoY to Rs 555 crore—Citi believes Cipla's earnings have likely bottomed out following the decline related to gRevlimid.
From a valuation perspective, Citi argues that Cipla offers more attractive exposure to the Indian pharmaceutical market than many of its peers. The brokerage pointed out that Cipla’s India business is valued at 7.8 times FY26 sales, which is notably more reasonable than Mankind Pharma, which trades at 8.5 times. Currently, the stock trades at 25x FY27E earnings and 21x FY28E earnings, suggesting a favorable risk-reward profile for long-term investors.
Key Takeaways
- Targeted Upside: Citi maintains a 'Buy' rating for Cipla with a target price of Rs 1,700, implying a 25.55% potential rally.
- US Growth Drivers: Upcoming approvals for gFlovent and the launch of gVentolin, alongside a 50% market share in US Nintedanib, are key growth triggers.
- Attractive Valuation: Cipla provides a more cost-effective entry point into the Indian pharma sector compared to peers like Mankind, trading at 7.8x FY26 sales for its India business.